Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.76 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504605 | 0.87 | HRH1 (0.64) | HRH1 | |
| SCHEMBL7472391 | 0.86 | HRH1 (0.57) | HRH1CYP2J2KCNH2CHRM3 | |
| SCHEMBL8983793 | 0.86 | CHRM3 (0.61) | HRH1CYP2J2CHRM3 | |
| SCHEMBL17031600 | 0.86 | HRH1 (1.00) | HRH1CYP2J2KCNH2 | |
| SCHEMBL17023774 | 0.85 | HRH1 (0.79) | HRH1CYP2J2KCNH2 | |
| SCHEMBL18609074 | 0.85 | HRH1 (0.79) | HRH1CYP2J2KCNH2 | |
| SCHEMBL17023783 | 0.85 | HRH1 (0.79) | HRH1CYP2J2KCNH2 | |
| SCHEMBL18609075 | 0.85 | HRH1 (0.79) | HRH1CYP2J2KCNH2 | |
| SCHEMBL7838031 | 0.84 | HRH1 (0.55) | HRH1CYP2J2KCNH2CHRM3 | |
| SCHEMBL17023773 | 0.84 | HRH1 (0.77) | HRH1CYP2J2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| EP-0399547-B1 | USE OF 4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDYL-PHENYLALKANE DERIVATIVES FOR THE MANUFACTURE OF AN ANTIHISTAMINIC | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1993-08-11 | — | — | EP | disclosed |
| US-5077301-A | 4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDYLPHENYLALKANE DERIVATIVES AS ANTIHISTAMINES AND METHODS OF TREATMENT OF AN ALLERGIC RESPONSE | SCHAPER & BRUEMMER GMBH & CO. KG (DE) | 1991-12-31 | — | — | US | disclosed |
| EP-0399547-A2 | Use of 4-(hydroxydiphenylmethyl)-1-piperidyl-phenylalkane derivatives for the manufacture of an antihistaminic | SCHAPER & BRÜMMER GMBH & CO. KG (DE) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | HRH1 1562/4885CYP2J2 2123/4885KCNH2 1413/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | HRH1 1562/4885CYP2J2 2123/4885KCNH2 1413/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | HRH1 1562/4885CYP2J2 2123/4885KCNH2 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.